Achieve Life Sciences Announces Up to $354M Private Placement

Achieve Life Sciences, a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to $354M.